Sana Biotechnology, Inc. has priced its public offering of common stock and pre-funded warrants, totaling approximately $75.0 million. The offering includes 20,895,522 shares of common stock and pre-funded warrants to purchase 1,492,537 shares. The underwriters have a 30-day option to purchase up to an additional 3,358,208 shares. The offering is expected to close on or about August 8, 2025, with Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen acting as joint book-running managers.

The offering is being made pursuant to a Registration Statement on Form S-3, with a base prospectus filed with the SEC. Final prospectus documents will also be filed. Interested parties can access these documents for free through the SEC’s website.

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. The company has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities.

Read more at GlobeNewswire: Sana Biotechnology Announces Pricing of Public Offering